GlassScriptPhysician profile
Brian R Thomas
NPI 1518101443
$1,003.25
in general payments reported to CMS, 2019-2025
32 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.78 · 2020: $19.53 · 2021: $80.01 · 2022: $91.50 · 2023: $217 · 2024: $301 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $120.51 | 2023-2024 | Dupixent, Libtayo |
| Dendreon Pharmaceuticals LLC | $117.38 | 2024-2025 | Provenge |
| Boston Scientific Corporation | $73.52 | 2021-2023 | Watchman Access System |
| Stryker Corporation | $58.51 | 2021-2022 | |
| Janssen Biotech, INC. | $39.75 | 2024-2025 | Rybrevant, Balversa, Akeega |
| Medtronic, INC. | $38.41 | 2025 | Stealthstation S8 Platform |
| Neurocrine Biosciences, INC. | $37.33 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $34.18 | 2022-2025 | Austedo Xr |
| Intercept Pharmaceuticals, INC. | $30.85 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.88 | 2023 | |
| Qol Medical, LLC | $28.82 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $25.46 | 2025 | Voquezna |
| Alkermes, INC. | $24.64 | 2024 | Aristada, Lybalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.15 | 2024 | Relistor |
| Pharmacosmos Therapeutics INC. | $23.08 | 2023 | Monoferric |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $22.77 | 2025 | Fanapt |
| Inspire Medical Systems, INC. | $22.56 | 2023 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.55 | 2023 | |
| Tg Therapeutics, INC. | $20.11 | 2023 | |
| Acclarent, INC | $19.53 | 2020 | |
| Ucb, INC. | $18.07 | 2024 | Fintepla |
| Otsuka America Pharmaceutical, INC. | $18.06 | 2024 | Rexulti, Abilify Maintena |
| Emd Serono, INC. | $17.29 | 2023 | Mavenclad |
| Ardelyx, INC. | $17.27 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $17.09 | 2025 | Zenpep |
| Bioxcel Therapeutics, INC. | $17.07 | 2024 | Igalmi |
| Janssen Pharmaceuticals, INC | $16.78 | 2022 | |
| Seagen INC. | $15.43 | 2023 | Adcetris |
| Csl Behring | $15.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.78 | 2019 | |
| Aerin Medical INC. | $12.52 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.